Skip to main content

Advertisement

SpringerLink
Log in

Treatment of gastrointestinal problems in cystic fibrosis

  • Published:
Current Treatment Options in Gastroenterology Aims and scope Submit manuscript

Opinion statement

The gastrointestinal (GI) manifestations of cystic fibrosis (CF) are varied and include pancreatic insufficiency, meconium ileus, distal intestinal obstruction syndrome (DIOS), liver disease, and other less common manifestations. Treatment of pancreatic insufficiency consists of providing appropriate pancreatic enzyme replacement therapy and may include raising duodenal pH to allow for optimal action of these enzymes. Despite a number of pancreatic enzyme replacement products, malabsorption cannot be normalized. Management of DIOS depends on the severity of the symptoms; adequate hydration is very important. Polyethylene glycol solutions are being increasingly used. The precipitating cause of the episode of DIOS should be looked for so future episodes can be prevented. Liver disease is relatively silent and annual monitoring of liver function and status is recommended. Treatment is mainly supportive and the role of ursodeoxycholic acid in the prevention of cirrhosis needs to be better defined. Nutritional status is an important part of management of all GI and liver manifestations of CF. A team approach and the assistance of a registered dietitian are extremely valuable in managing the GI and liver manifestations of CF.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Stern RC, Eisenberg JD, Wagener JS, et al.: A comparison of the efficacy and tolerance of pancrelipase and placebo in the treatment of steatorrhea in cystic fibrosis patients with clinical exocrine pancreatic insufficiency. Am J Gastroenterol 2000, 95:1932–1938.

    Article  PubMed  CAS  Google Scholar 

  2. Millar-Jones L, Goodchild MC: Cystic fibrosis, pancreatic sufficiency and distal intestinal obstruction syndrome: a report of four cases. Acta Paediatr 1995, 84:577–578.

    PubMed  CAS  Google Scholar 

  3. Zielenski J, Corey M, Rozmahel R, et al.: Detection of a cystic fibrosis modifier locus for meconium ileus on human chromosome 19q13. Nat Genet 1999, 2:128–129.

    Google Scholar 

  4. Minkes RK, Langer JC, Skinner MA, et al.: Intestinal obstruction after lung transplantation in children with cystic fibrosis. J Pediatr Surg 1999, 34:1489–1493.

    Article  PubMed  CAS  Google Scholar 

  5. Coughlin JP, Gauderer MW, Stern RC, et al.: The spectrum of appendiceal disease in cystic fibrosis. J Pediatr Surg 1990, 25:835–839.

    Article  PubMed  CAS  Google Scholar 

  6. Del Pin CA, Czyrko C, Ziegler MM, et al.: Management and survival of meconium ileus—a 30-year review. Ann Surg 1992, 215:179–185.

    Article  PubMed  Google Scholar 

  7. Baker SS, Liptak GS, Colletti RB, et al.: Constipation in infants and children: evaluation and treatment. J Pediatr Gastroenterol Nutr 1999, 29:612–626.

    Article  PubMed  CAS  Google Scholar 

  8. Pashankar DS, Bishop WP: Efficacy and optimal dose of daily polyethylene glycol 3350 for treatment of constipation and encopresis in children. J Pediatr 2001, 139:428–432.

    Article  PubMed  CAS  Google Scholar 

  9. Rubinstein S, Moss R, Lewiston N: Constipation and meconium ileus equivalent in patients with cystic fibrosis. Pediatrics 1986, 78:473–479.

    PubMed  CAS  Google Scholar 

  10. Siafakas C, Vottler TP, Andersen JM: Rectal prolapse in pediatrics. Clin Pediatr 1999, 38:63–72.

    CAS  Google Scholar 

  11. Rudolph CD: Guidelines for evaluation and treatment of gastroesophageal reflux in infants and children. Recommendations of the North American Society for Pediatric Gastroenterology and Nutriiton. J Pediatr Gastroenterol Nutr 2001, 32(suppl 2):S1-S31.

    Article  PubMed  Google Scholar 

  12. Hassall E, Israel DM, Davidson AG, et al.: Barrett’s esophagus in children with cystic fibrosis: not a coincidental association. Am J Gastroenterol 1993, 8:1934–1938.

    Google Scholar 

  13. Lewindon PJ, Robb TA, Moore DJ, et al.: Bowel dysfunction in cystic fibrosis: importance of breath testing. J Paediatr Child Health 1998, 34:79–82.

    Article  PubMed  CAS  Google Scholar 

  14. Sharar N, Schwarz M, Malone G, et al.: Mutations of the cystic fibrosis gene in patients with chronic pancreatitis. N Engl J Med 1998, 339:645–652.

    Article  Google Scholar 

  15. Noone PG, Zhou Z, Silverman LM, et al.: Cystic fibrosis gene mutations and pancreatic risk: relation to epithelial ion transport and trypsin inhibitor gene mutations. Gastroenterology 2001, 121:1310–1319.

    Article  PubMed  CAS  Google Scholar 

  16. Borowitz DS, Grand RJ, Durie PR, et al.: Use of pancreatic enzyme supplements with cystic fibrosis in the context of fibrosing colonopathy. J Pediatr 2001, 127:681–684. This is the first and most comprehensive report from the CF Foundation with guidelines for pancreatic enzyme-replacement therapy and management.

    Google Scholar 

  17. FitzSimmons SC, Burkhart GA, Borowitz D, et al.: Highdose pancreatic enzyme supplements and fibrosing colonopathy in children with cystic fibrosis. N Engl J Med 1997, 336:1283–1289.

    Article  PubMed  CAS  Google Scholar 

  18. Lloyd-Still JD, Beno DW, Kimura RM: Cystic fibrosing colonopathy. Curr Gastroenterol Rep 1999, 1:231–237.

    Article  PubMed  CAS  Google Scholar 

  19. Chaun H: Colonic disorders in adult cystic fibrosis. Can J Gastroenterol 2001, 15:586–590.

    PubMed  CAS  Google Scholar 

  20. Neglia J, FitzSimmons SC, Maisonneuve P, et al.: The risk of cancer among patients with cystic fibrosis. N Engl J Med 1995, 332:494–499.

    Article  PubMed  CAS  Google Scholar 

  21. Baker RD, Borowitz D, Stallings VA: Consensus report on nutrition for pediatric patients with cystic fibrosis. J Pediatr Gastroenterol Nutr 2002, 35:246–259. This is a comprehensive summary of the nutritional aspects of the management in CF and provides the reader with some excellent information.

    Article  PubMed  Google Scholar 

  22. Kraisinger M, Hochhaus G, Stecenko A, et al.: Clinical pharmacology of pancreatic enzymes in patients with cystic fibrosis and in vitro performance of microencapsulated formulations. J Clin Pharmacol 1994, 34:158–166.

    PubMed  CAS  Google Scholar 

  23. Meyer JH, Lake R: Mismatch of duodenal deliveries of dietary fat and pancreatin from enterically coated microspheres. Pancreas 1997, 15:226–235.

    Article  PubMed  CAS  Google Scholar 

  24. Hendeles L, Dorf A, Stecenko A, et al.: Treatment failure after substitution of generic pancrelipase capsules. JAMA 1990, 263:2459–2461.

    Article  PubMed  CAS  Google Scholar 

  25. Durie PR, Bell L, Linton W, et al.: Effect of cimetidine and sodium bicarbonate on pancreatic replacement therapy in cystic fibrosis. Gut 1980, 21:778–786.

    PubMed  CAS  Google Scholar 

  26. Tran TM, Van den Neucker A, Hendriks JJ, et al.: Effects of a proton-pump inhibitor in cystic fibrosis. Acta Paediatr 1998, 87:553–558.

    Article  PubMed  CAS  Google Scholar 

  27. DiMagno EP: Gastric acid suppression and treatment of severe exocrine pancreatic insufficiency. Best Practice Res Clin Gastroenterol 2001, 15:477–486.

    Article  CAS  Google Scholar 

  28. Kreimler S, Wilk B, Schurer W, et al.: Preventing dehydration in children with cystic fibrosis who exercise in the heat. Med Sci Spots Exerc 1999, 31:774–779.

    Article  Google Scholar 

  29. Koletzko S, Stringer DA, Cleghorn GJ, et al.: Lavage treatment of distal obstruction intestinal syndrome in children with cystic fibrosis. Pediatrics 1989, 83:727–733.

    PubMed  CAS  Google Scholar 

  30. Ellis GJ, Dewar AL, Rolles CJ, et al.: Dietary fiber and the occurrence of gut symptoms in cystic fibrosis. Arch Dis Child 1997, 76:35–37.

    Article  PubMed  Google Scholar 

  31. Sokol RJ, Durie PR, and the CF Foundation Hepatobiliary disease consensus group: Recommendations for the management of liver and biliary tract disease in cystic fibrosis. J Pediatr Gastenterol Nutr 1999, 28:S1-S13.

    Article  Google Scholar 

  32. Colombo C, Battezzati PM, Podda M, et al.: Ursodeoxycholic acid for liver disease associated with cystic fibrosis: a double-blind multicenter trial. The Italian group for the study of ursodeoxycholic acid in cystic fibrosis. Hepatology 1996, 23:1484–1490.

    Article  PubMed  CAS  Google Scholar 

  33. Lindblad A, Glaumann H, Strandvick B: A two-year prospective study of the effect of ursodeoxycholic acid on urinary bile acid excretion and liver morphology in cystic fibrosis-associated liver disease. Hepatology 1998, 27:166–174.

    Article  PubMed  CAS  Google Scholar 

  34. Narkewicz MR, Smith D, Gregory C, et al.: Effect of ursodeoxyholic acid therapy on hepatic function in children with intrahepatic cholestasis. J Pediatr Gastro Nutr 1998, 26:49–55.

    Article  CAS  Google Scholar 

  35. Paumgartner G: Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525–531.

    Article  PubMed  CAS  Google Scholar 

  36. Colombo C, Crosgnani A, Assaisso M, et al.: Ursodeoxycholic therapy in cystic fibrosis-associated liver disease: a dose-response study. Hepatology 1992, 16:924–930.

    Article  PubMed  CAS  Google Scholar 

  37. Cheng K, Ashby D, Smythe R: Ursodeoxycholic acid for cystic fibrosis-related liver disease. Cochrane Database of Systematic Reviews 2000, 2:CD000222.

    Google Scholar 

  38. Colombo C, Bertolini E, Assaisso ML, et al.: Failure of ursodeoxycholic acid to dissolve radiolucent gallstones in patients with cystic fibrosis. Acta Paeditr 1993, 82:562–565.

    CAS  Google Scholar 

  39. Strandvick B, Hultcrantz R: Liver function and morphology during long-term fatty acid supplementation in cystic fibrosis. Liver 1994, 14:32–36.

    Google Scholar 

  40. Debray D, Lykavieris P, Gauthier F, et al.: Outcome of cystic fibrosis-associated liver cirrhosis: management of portal hypertension. J Hepatol 1999, 31:77–83.

    Article  PubMed  CAS  Google Scholar 

  41. Genyk YS, Quiros JA, Jabbour N, et al.: Liver transplantation in cystic fibrosis. Curr Opin Pulmon Med 2001, 7:441–447.

    Article  CAS  Google Scholar 

  42. Lindblad A, Glaumann H, Strandvik B: Natural history of liver disease in cystic fibrosis. Hepatology 1999, 30:1151–1158.

    Article  PubMed  CAS  Google Scholar 

  43. Diwakar V, Pearson L, Beath S: Liver disease in children with cystic fibrosis. Paediatric Resp Rev 2001, 2:340–349.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of GI and Nutrition, The Children’s Hospital of Philadelphia, 34th Street & Civic Center Boulevard, 19104, Philadelphia, PA, USA

    Maria R. Mascarenhas MD

  2. Division of GI and Nutrition, University of Pennsylvania School of Medicine, 34th Street & Civic Center Boulevard, 19104, Philadelphia, PA, USA

    Maria R. Mascarenhas MD

Authors
  1. Maria R. Mascarenhas MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Mascarenhas, M.R. Treatment of gastrointestinal problems in cystic fibrosis. Curr Treat Options Gastro 6, 427–441 (2003). https://doi.org/10.1007/s11938-003-0045-2

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11938-003-0045-2

Keywords

Search

Navigation